Table of Content

1 Market Overview of Neurodegenerative Disease
1.1 Neurodegenerative Disease Market Overview
1.1.1 Neurodegenerative Disease Product Scope
1.1.2 Neurodegenerative Disease Market Status and Outlook
1.2 Global Neurodegenerative Disease Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Neurodegenerative Disease Market Size by Region (2018-2029)
1.4 Global Neurodegenerative Disease Historic Market Size by Region (2018-2024)
1.5 Global Neurodegenerative Disease Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Neurodegenerative Disease Market Size (2018-2029)
1.6.1 North America Neurodegenerative Disease Market Size (2018-2029)
1.6.2 Europe Neurodegenerative Disease Market Size (2018-2029)
1.6.3 Asia-Pacific Neurodegenerative Disease Market Size (2018-2029)
1.6.4 Latin America Neurodegenerative Disease Market Size (2018-2029)
1.6.5 Middle East & Africa Neurodegenerative Disease Market Size (2018-2029)
2 Neurodegenerative Disease Market by Type
2.1 Introduction
2.1.1 NMDA
2.1.2 SSRIs
2.1.3 Dopamine Inhibitors
2.2 Global Neurodegenerative Disease Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Neurodegenerative Disease Historic Market Size by Type (2018-2024)
2.2.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
3 Neurodegenerative Disease Market Overview by Application
3.1 Introduction
3.1.1 Parkinson’s Disease
3.1.2 Huntington Disease
3.1.3 Amyotrophic Lateral Sclerosis
3.1.4 Alzheimer’s Disease
3.2 Global Neurodegenerative Disease Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Neurodegenerative Disease Historic Market Size by Application (2018-2024)
3.2.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
4 Neurodegenerative Disease Competition Analysis by Players
4.1 Global Neurodegenerative Disease Market Size by Players (2018-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
4.3 Date of Key Players Enter into Neurodegenerative Disease Market
4.4 Global Top Players Neurodegenerative Disease Headquarters and Area Served
4.5 Key Players Neurodegenerative Disease Product Solution and Service
4.6 Competitive Status
4.6.1 Neurodegenerative Disease Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Neurodegenerative Disease Products, Services and Solutions
5.1.4 Novartis Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.1.5 Novartis Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Neurodegenerative Disease Products, Services and Solutions
5.2.4 Pfizer Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.2.5 Pfizer Recent Developments
5.3 Merck Serono
5.3.1 Merck Serono Profile
5.3.2 Merck Serono Main Business
5.3.3 Merck Serono Neurodegenerative Disease Products, Services and Solutions
5.3.4 Merck Serono Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.3.5 Biogen Idec Recent Developments
5.4 Biogen Idec
5.4.1 Biogen Idec Profile
5.4.2 Biogen Idec Main Business
5.4.3 Biogen Idec Neurodegenerative Disease Products, Services and Solutions
5.4.4 Biogen Idec Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.4.5 Biogen Idec Recent Developments
5.5 TEVA
5.5.1 TEVA Profile
5.5.2 TEVA Main Business
5.5.3 TEVA Neurodegenerative Disease Products, Services and Solutions
5.5.4 TEVA Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.5.5 TEVA Recent Developments
5.6 UCB
5.6.1 UCB Profile
5.6.2 UCB Main Business
5.6.3 UCB Neurodegenerative Disease Products, Services and Solutions
5.6.4 UCB Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.6.5 UCB Recent Developments
5.7 Boehringer Ingelheim
5.7.1 Boehringer Ingelheim Profile
5.7.2 Boehringer Ingelheim Main Business
5.7.3 Boehringer Ingelheim Neurodegenerative Disease Products, Services and Solutions
5.7.4 Boehringer Ingelheim Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.7.5 Boehringer Ingelheim Recent Developments
5.8 Sanofi
5.8.1 Sanofi Profile
5.8.2 Sanofi Main Business
5.8.3 Sanofi Neurodegenerative Disease Products, Services and Solutions
5.8.4 Sanofi Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.8.5 Sanofi Recent Developments
5.9 GlaxoSmithKline
5.9.1 GlaxoSmithKline Profile
5.9.2 GlaxoSmithKline Main Business
5.9.3 GlaxoSmithKline Neurodegenerative Disease Products, Services and Solutions
5.9.4 GlaxoSmithKline Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.9.5 GlaxoSmithKline Recent Developments
5.10 Livzon Pharmaceutical
5.10.1 Livzon Pharmaceutical Profile
5.10.2 Livzon Pharmaceutical Main Business
5.10.3 Livzon Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.10.4 Livzon Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.10.5 Livzon Pharmaceutical Recent Developments
5.11 Haisco Pharmaceutical
5.11.1 Haisco Pharmaceutical Profile
5.11.2 Haisco Pharmaceutical Main Business
5.11.3 Haisco Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.11.4 Haisco Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.11.5 Haisco Pharmaceutical Recent Developments
5.12 Jingxin Pharmaceutical
5.12.1 Jingxin Pharmaceutical Profile
5.12.2 Jingxin Pharmaceutical Main Business
5.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.12.4 Jingxin Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.12.5 Jingxin Pharmaceutical Recent Developments
5.13 Dongcheng Biochemicals
5.13.1 Dongcheng Biochemicals Profile
5.13.2 Dongcheng Biochemicals Main Business
5.13.3 Dongcheng Biochemicals Neurodegenerative Disease Products, Services and Solutions
5.13.4 Dongcheng Biochemicals Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.13.5 Dongcheng Biochemicals Recent Developments
5.14 Hisun Pharmaceutical
5.14.1 Hisun Pharmaceutical Profile
5.14.2 Hisun Pharmaceutical Main Business
5.14.3 Hisun Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.14.4 Hisun Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.14.5 Hisun Pharmaceutical Recent Developments
5.15 Luye Pharma
5.15.1 Luye Pharma Profile
5.15.2 Luye Pharma Main Business
5.15.3 Luye Pharma Neurodegenerative Disease Products, Services and Solutions
5.15.4 Luye Pharma Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.15.5 Luye Pharma Recent Developments
5.16 Ark Pharmaceutical
5.16.1 Ark Pharmaceutical Profile
5.16.2 Ark Pharmaceutical Main Business
5.16.3 Ark Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.16.4 Ark Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.16.5 Ark Pharmaceutical Recent Developments
5.17 Kanghong Pharmaceutical
5.17.1 Kanghong Pharmaceutical Profile
5.17.2 Kanghong Pharmaceutical Main Business
5.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.17.4 Kanghong Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.17.5 Kanghong Pharmaceutical Recent Developments
5.18 Huahai Pharmaceutical
5.18.1 Huahai Pharmaceutical Profile
5.18.2 Huahai Pharmaceutical Main Business
5.18.3 Huahai Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.18.4 Huahai Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.18.5 Huahai Pharmaceutical Recent Developments
5.19 BORA PHARMACEUTICALS
5.19.1 BORA PHARMACEUTICALS Profile
5.19.2 BORA PHARMACEUTICALS Main Business
5.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Products, Services and Solutions
5.19.4 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue (US$ Million) & (2018-2024)
5.19.5 BORA PHARMACEUTICALS Recent Developments
6 North America
6.1 North America Neurodegenerative Disease Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Neurodegenerative Disease Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Neurodegenerative Disease Market Dynamics
11.1 Neurodegenerative Disease Industry Trends
11.2 Neurodegenerative Disease Market Drivers
11.3 Neurodegenerative Disease Market Challenges
11.4 Neurodegenerative Disease Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Neurodegenerative Disease Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
Table 2. Global Neurodegenerative Disease Market Size by Region (2018-2024) & (US$ Million)
Table 3. Global Neurodegenerative Disease Market Size Share by Region (2018-2024)
Table 4. Global Neurodegenerative Disease Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 5. Global Neurodegenerative Disease Forecasted Market Size Share by Region (2024-2029)
Table 6. Global Neurodegenerative Disease Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
Table 7. Global Neurodegenerative Disease Market Size by Type (2018-2024) & (US$ Million)
Table 8. Global Neurodegenerative Disease Revenue Market Share by Type (2018-2024)
Table 9. Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 10. Global Neurodegenerative Disease Revenue Market Share by Type (2024-2029)
Table 11. North America Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 12. North America Neurodegenerative Disease Revenue by Type (2024-2029) & (US$ Million)
Table 13. Europe Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 14. Europe Neurodegenerative Disease Revenue by Type (2024-2029) & (US$ Million)
Table 15. Asia-Pacific Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 16. Asia-Pacific Neurodegenerative Disease Revenue by Type (2024-2029) & (US$ Million)
Table 17. Latin America Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 18. Latin America Neurodegenerative Disease Revenue by Type (2024-2029) & (US$ Million)
Table 19. Middle East and Africa Neurodegenerative Disease Revenue by Type (2018-2024) & (US$ Million)
Table 20. Middle East and Africa Neurodegenerative Disease Revenue by Type (2024-2029) & (US$ Million)
Table 21. Global Neurodegenerative Disease Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
Table 22. Global Neurodegenerative Disease Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Neurodegenerative Disease Revenue Market Share by Application (2018-2024)
Table 24. Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 25. Global Neurodegenerative Disease Revenue Market Share by Application (2024-2029)
Table 26. North America Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 27. North America Neurodegenerative Disease Revenue by Application (2024-2029) & (US$ Million)
Table 28. Europe Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 29. Europe Neurodegenerative Disease Revenue by Application (2024-2029) & (US$ Million)
Table 30. Asia-Pacific Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 31. Asia-Pacific Neurodegenerative Disease Revenue by Application (2024-2029) & (US$ Million)
Table 32. Latin America Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 33. Latin America Neurodegenerative Disease Revenue by Application (2024-2029) & (US$ Million)
Table 34. Middle East and Africa Neurodegenerative Disease Revenue by Application (2018-2024) & (US$ Million)
Table 35. Middle East and Africa Neurodegenerative Disease Revenue by Application (2024-2029) & (US$ Million)
Table 36. Global Neurodegenerative Disease Revenue (US$ Million) by Players (2018-2024)
Table 37. Global Neurodegenerative Disease Revenue Market Share by Players (2018-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Table 39. Date of Key Players Enter into Neurodegenerative Disease Market
Table 40. Global Neurodegenerative Disease Key Players Headquarters and Area Served
Table 41. Neurodegenerative Disease Product Solution and Service
Table 42. Global Neurodegenerative Disease Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Novartis Basic Information List
Table 45. Novartis Description and Business Overview
Table 46. Novartis Neurodegenerative Disease Products, Services and Solutions
Table 47. Revenue (US$ Million) in Neurodegenerative Disease Business of Novartis (2018-2024)
Table 48. Novartis Recent Developments
Table 49. Pfizer Basic Information List
Table 50. Pfizer Description and Business Overview
Table 51. Pfizer Neurodegenerative Disease Products, Services and Solutions
Table 52. Revenue (US$ Million) in Neurodegenerative Disease Business of Pfizer (2018-2024)
Table 53. Pfizer Recent Developments
Table 54. Merck Serono Basic Information List
Table 55. Merck Serono Description and Business Overview
Table 56. Merck Serono Neurodegenerative Disease Products, Services and Solutions
Table 57. Revenue (US$ Million) in Neurodegenerative Disease Business of Merck Serono (2018-2024)
Table 58. Merck Serono Recent Developments
Table 59. Biogen Idec Basic Information List
Table 60. Biogen Idec Description and Business Overview
Table 61. Biogen Idec Neurodegenerative Disease Products, Services and Solutions
Table 62. Revenue (US$ Million) in Neurodegenerative Disease Business of Biogen Idec (2018-2024)
Table 63. Biogen Idec Recent Developments
Table 64. TEVA Basic Information List
Table 65. TEVA Description and Business Overview
Table 66. TEVA Neurodegenerative Disease Products, Services and Solutions
Table 67. Revenue (US$ Million) in Neurodegenerative Disease Business of TEVA (2018-2024)
Table 68. TEVA Recent Developments
Table 69. UCB Basic Information List
Table 70. UCB Description and Business Overview
Table 71. UCB Neurodegenerative Disease Products, Services and Solutions
Table 72. Revenue (US$ Million) in Neurodegenerative Disease Business of UCB (2018-2024)
Table 73. UCB Recent Developments
Table 74. Boehringer Ingelheim Basic Information List
Table 75. Boehringer Ingelheim Description and Business Overview
Table 76. Boehringer Ingelheim Neurodegenerative Disease Products, Services and Solutions
Table 77. Revenue (US$ Million) in Neurodegenerative Disease Business of Boehringer Ingelheim (2018-2024)
Table 78. Boehringer Ingelheim Recent Developments
Table 79. Sanofi Basic Information List
Table 80. Sanofi Description and Business Overview
Table 81. Sanofi Neurodegenerative Disease Products, Services and Solutions
Table 82. Revenue (US$ Million) in Neurodegenerative Disease Business of Sanofi (2018-2024)
Table 83. Sanofi Recent Developments
Table 84. GlaxoSmithKline Basic Information List
Table 85. GlaxoSmithKline Description and Business Overview
Table 86. GlaxoSmithKline Neurodegenerative Disease Products, Services and Solutions
Table 87. Revenue (US$ Million) in Neurodegenerative Disease Business of GlaxoSmithKline (2018-2024)
Table 88. GlaxoSmithKline Recent Developments
Table 89. Livzon Pharmaceutical Basic Information List
Table 90. Livzon Pharmaceutical Description and Business Overview
Table 91. Livzon Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
Table 92. Revenue (US$ Million) in Neurodegenerative Disease Business of Livzon Pharmaceutical (2018-2024)
Table 93. Livzon Pharmaceutical Recent Developments
Table 94. Haisco Pharmaceutical Basic Information List
Table 95. Haisco Pharmaceutical Description and Business Overview
Table 96. Haisco Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
Table 97. Revenue (US$ Million) in Neurodegenerative Disease Business of Haisco Pharmaceutical (2018-2024)
Table 98. Haisco Pharmaceutical Recent Developments
Table 99. Jingxin Pharmaceutical Basic Information List
Table 100. Jingxin Pharmaceutical Description and Business Overview
Table 101. Jingxin Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
Table 102. Revenue (US$ Million) in Neurodegenerative Disease Business of Jingxin Pharmaceutical (2018-2024)
Table 103. Jingxin Pharmaceutical Recent Developments
Table 104. Dongcheng Biochemicals Basic Information List
Table 105. Dongcheng Biochemicals Description and Business Overview
Table 106. Dongcheng Biochemicals Neurodegenerative Disease Products, Services and Solutions
Table 107. Revenue (US$ Million) in Neurodegenerative Disease Business of Dongcheng Biochemicals (2018-2024)
Table 108. Dongcheng Biochemicals Recent Developments
Table 109. Hisun Pharmaceutical Basic Information List
Table 110. Hisun Pharmaceutical Description and Business Overview
Table 111. Hisun Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
Table 112. Revenue (US$ Million) in Neurodegenerative Disease Business of Hisun Pharmaceutical (2018-2024)
Table 113. Hisun Pharmaceutical Recent Developments
Table 114. Luye Pharma Basic Information List
Table 115. Luye Pharma Description and Business Overview
Table 116. Luye Pharma Neurodegenerative Disease Products, Services and Solutions
Table 117. Revenue (US$ Million) in Neurodegenerative Disease Business of Luye Pharma (2018-2024)
Table 118. Luye Pharma Recent Developments
Table 119. Ark Pharmaceutical Basic Information List
Table 120. Ark Pharmaceutical Description and Business Overview
Table 121. Ark Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
Table 122. Revenue (US$ Million) in Neurodegenerative Disease Business of Ark Pharmaceutical (2018-2024)
Table 123. Ark Pharmaceutical Recent Developments
Table 124. Kanghong Pharmaceutical Basic Information List
Table 125. Kanghong Pharmaceutical Description and Business Overview
Table 126. Kanghong Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
Table 127. Revenue (US$ Million) in Neurodegenerative Disease Business of Kanghong Pharmaceutical (2018-2024)
Table 128. Kanghong Pharmaceutical Recent Developments
Table 129. Huahai Pharmaceutical Basic Information List
Table 130. Huahai Pharmaceutical Description and Business Overview
Table 131. Huahai Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
Table 132. Revenue (US$ Million) in Neurodegenerative Disease Business of Huahai Pharmaceutical (2018-2024)
Table 133. Huahai Pharmaceutical Recent Developments
Table 134. BORA PHARMACEUTICALS Basic Information List
Table 135. BORA PHARMACEUTICALS Description and Business Overview
Table 136. BORA PHARMACEUTICALS Neurodegenerative Disease Products, Services and Solutions
Table 137. Revenue (US$ Million) in Neurodegenerative Disease Business of BORA PHARMACEUTICALS (2018-2024)
Table 138. BORA PHARMACEUTICALS Recent Developments
Table 139. North America Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 140. North America Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 141. Europe Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 142. Europe Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 143. Asia-Pacific Neurodegenerative Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 144. Asia-Pacific Neurodegenerative Disease Market Size by Region (2018-2024) & (US$ Million)
Table 145. Asia-Pacific Neurodegenerative Disease Market Size by Region (2024-2029) & (US$ Million)
Table 146. Asia-Pacific Neurodegenerative Disease Market Share by Region (2018-2024)
Table 147. Asia-Pacific Neurodegenerative Disease Market Share by Region (2024-2029)
Table 148. Latin America Neurodegenerative Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 149. Latin America Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 150. Latin America Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 151. Middle East & Africa Neurodegenerative Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 152. Middle East & Africa Neurodegenerative Disease Market Size by Country (2018-2024) & (US$ Million)
Table 153. Middle East & Africa Neurodegenerative Disease Market Size by Country (2024-2029) & (US$ Million)
Table 154. Neurodegenerative Disease Market Trends
Table 155. Neurodegenerative Disease Market Drivers
Table 156. Neurodegenerative Disease Market Challenges
Table 157. Neurodegenerative Disease Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disease Market Size Year-over-Year 2018-2029 & (US$ Million)
Figure 2. Global Neurodegenerative Disease Market Size (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Neurodegenerative Disease Market Share by Regions: 2022 VS 2029
Figure 4. Global Neurodegenerative Disease Forecasted Market Size Share by Region (2024-2029)
Figure 5. North America Neurodegenerative Disease Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 6. Europe Neurodegenerative Disease Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 7. Asia-Pacific Neurodegenerative Disease Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 8. Latin America Neurodegenerative Disease Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 9. Middle East & Africa Neurodegenerative Disease Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 10. Product Picture of NMDA
Figure 11. Global NMDA Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 12. Product Picture of SSRIs
Figure 13. Global SSRIs Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 14. Product Picture of Dopamine Inhibitors
Figure 15. Global Dopamine Inhibitors Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 16. Global Neurodegenerative Disease Market Size Share by Type: 2022 & 2029
Figure 17. North America Neurodegenerative Disease Revenue Market Share by Type (2018-2029)
Figure 18. Europe Neurodegenerative Disease Revenue Market Share by Type (2018-2029)
Figure 19. Asia-Pacific Neurodegenerative Disease Revenue Market Share by Type (2018-2029)
Figure 20. Latin America Neurodegenerative Disease Revenue Market Share by Type (2018-2029)
Figure 21. Middle East and Africa Neurodegenerative Disease Revenue Market Share by Type (2018-2029)
Figure 22. Parkinson’s Disease Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 23. Huntington Disease Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 24. Amyotrophic Lateral Sclerosis Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 25. Alzheimer’s Disease Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 26. Global Neurodegenerative Disease Market Size Share by Application: 2022 & 2029
Figure 27. North America Neurodegenerative Disease Revenue Market Share by Application (2018-2029)
Figure 28. Europe Neurodegenerative Disease Revenue Market Share by Application (2018-2029)
Figure 29. Asia-Pacific Neurodegenerative Disease Revenue Market Share by Application (2018-2029)
Figure 30. Latin America Neurodegenerative Disease Revenue Market Share by Application (2018-2029)
Figure 31. Middle East and Africa Neurodegenerative Disease Revenue Market Share by Application (2018-2029)
Figure 32. Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 33. Global Top 5 and Top 10 Players Neurodegenerative Disease Market Share in 2022
Figure 34. North America Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 35. United States Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 36. Canada Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 37. Germany Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 38. France Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 39. U.K. Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 40. Italy Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 41. Russia Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 42. Nordic Countries Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 43. Asia-Pacific Neurodegenerative Disease Market Share by Region (2018-2029)
Figure 44. China Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 45. Japan Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 46. South Korea Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 47. Southeast Asia Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 48. India Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 49. Australia Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 50. Latin America Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 51. Mexico Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 52. Brazil Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 53. Middle East & Africa Neurodegenerative Disease Market Share by Country (2018-2029)
Figure 54. Turkey Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 56. UAE Neurodegenerative Disease Market Size (2018-2029) & (US$ Million)
Figure 57. Bottom-up and Top-down Approaches for This Report